Dr. Xiaohui Bi joins the lab to work on molecular and biological studies of Merkel cell carcinoma. She will use high resolution array-comparative genomic hybridization (CGH) to discover chromosomal copy number alterations (CNAs) that may indicate tumor suppressors (loss of region) and oncogenes (gain of region) in collaboration with Dr. Lynda Chin at the Dana-Farber Cancer Institute. She will also use large scale lentiviral siRNA-based screening in Merkel cell carcinoma cell lines to search for kinases/signaling pathways that are essential for this cell type to grow. siRNA-based screening will be a collaboration with Dr. William Hahn at the Dana-Farber Cancer Institute. Dr. Bi brings a high level of experience in cancer biology and cell cycle biology with her from her postdoctoral fellowship with Dr. Cyrus Vaziri at Boston Medical Center.
The authoritative source on Merkel cell carcinoma.
December 27, 2019